Breaking News

Clondalkin Group Appoints CEO

February 4, 2013

Lennon to head global business development plans

David Lennon has been appointed global chief executive officer of the Pharmaceutical and Healthcare Division at Clondalkin Group. Mr. Lennon will head Clondalkin’s global business development plans and will work closely with the European and North American management teams. The division has invested almost $300 million during the past five years and plans to significantly increase the international packaging group’s geographical footprint and expand its current product offering.
 
Mr. Lennon joined the company in 2009 as chief executive officer of the European Pharma and Healthcare division. Mr. Lennon was responsible for the expansion of accredited pharmaceutical packaging facilities from three to eight sites through growth and strategic acquisition.
 
Clondalkin Group chief executive Norbert McDermott said, “We appointed David in 2009 because his pedigree as a senior executive as well as his packaging business expertise was clear.  In his four years with Clondalkin Group he has continued to prove himself to be an invaluable leader in consolidating our position as a leading producer of secondary pharmaceutical packaging where we now operate from 18 sites in North America and Europe. I am delighted to have David heading up the global development strategy of our Pharmaceutical and Healthcare Division and am confident of our continued success.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important